lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma

• Published in: Aging (Albany, NY.) Vol. 15; no. 10; pp. 4510 - 4523
• Main Authors: Wang, Qiang, Xiao, GuangJun, Li, Na, Jiang, Xiulin, Li, Chunhong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals 31.05.2023
• Subjects: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung - pathology; DNA-Binding Proteins - genetics; Down-Regulation; Humans; Integrins - metabolism; Lung - pathology; Lung Neoplasms - pathology; Prognosis; Research Paper; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; RNA-Binding Proteins - genetics; Tumor Microenvironment; lncRNA; immune checkpoint inhibitors; NSCLC; integrin alpha L; immunotherapy
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.204756

Integrin alpha L (ITGAL) seemed to play a critical role in carcinogenesis and immune regulation. Nevertheless, the effects of ITGAL on non-small cell lung cancer (NSCLC) remain elusive. The present paper intended to determine the effects of ITGAL in NSCLC via the integration of bioinformatic analyses. In this study, we found that the mRNA and protein levels of ITGAL were downregulated in NSCLC tissues. Significantly, low ITGAL expression was related to poorer prognosis and increased malignancy of NSCLC. In addition, GO analysis and KEGG pathway analysis revealed that the coexpressed genes of ITGAL were predominantly associated with various immune-associated signaling pathways, like the T cell receptor signaling pathway, Th17 cell differentiation, chemokine signaling pathway, and NF-κB signaling pathway. Our result indicated that lncRNA-mediated downregulation of integrin alpha L expression was tightly related to immunocyte infiltration, immune modulators, and chemotactic factors in NSCLC, which potentially serves as a biomarker for clinical prognosis prediction and immunotherapy of NSCLC. This is the first comprehensive analysis of ITGAL in the prognosis, immune microenvironment, and immunotherapy of lung adenocarcinoma. ITGAL are promising biomarkers for predicting clinical outcomes and immunotherapy responses in patients with NSCLC.